Placebo will be administered for 12 weeks

DOUBLE-BLIND STUDY MULTICENTRIC RANDOMIZED BY PARALLEL GROUPS CONTROLLED BY PLACEBO AND ACTIVE COMPARATOR CONDUCTED UNDER BLIND INTERNAL CONDITIONS TO DETERMINE THE INCIDENCE OF GASTRODUODENAL ULCERAS IN PATIENTS WITH OSTEOARTHRITIS AFTER 12 TREATMENT WITH MK-0663, IBUPROFENO OR PLACEBO

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of BMS-207940, a Selective Endothelina Receptor, Antangonist, in Subjects with Intermittent Claudication